Tango Therapeutics Q1 2024 GAAP EPS $(0.35) Misses $(0.31) Estimate, Sales $6.471M Miss $6.669M Estimate
Tango Therapeutics Q1 2024 GAAP EPS $(0.35) Misses $(0.31) Estimate, Sales $6.471M Miss $6.669M Estimate
Tango Therapeutics 2024年第一季度公認會計准則每股收益美元（0.35）未達到預期（0.31）美元，銷售額爲64.71億美元，低於預期的666.9萬美元
Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.31) by 12.9 percent. This is a 9.37 percent decrease over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $6.471 million which missed the analyst consensus estimate of $6.669 million by 2.98 percent. This is a 12.23 percent increase over sales of $5.766 million the same period last year.
Tango Therapeutics（納斯達克股票代碼：TNGX）公佈的季度虧損爲每股0.35美元，比分析師普遍預期的0.31美元（0.31美元）低12.9％。與去年同期每股虧損0.32美元（0.32美元）相比，下降了9.37％。該公司公佈的季度銷售額爲647.1萬美元，比分析師共識估計的666.9萬美元低2.98％。這比去年同期的576.6萬美元的銷售額增長了12.23％。